NASDAQ:SYRE Spyre Therapeutics (SYRE) Stock Price, News & Analysis $98.63 -2.83 (-2.79%) As of 10:39 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Spyre Therapeutics Stock (NASDAQ:SYRE) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Spyre Therapeutics alerts:Sign Up Key Stats Today's Range$99.00▼$103.5050-Day Range$78.63▼$109.0052-Week Range$23.01▼$110.64Volume119,890 shsAverage Volume1.12 million shsMarket Capitalization$9.37 billionP/E RatioN/ADividend YieldN/APrice Target$110.53Consensus RatingModerate Buy Company Overview Spyre Therapeutics is a clinical-stage biotechnology company developing antibody-based medicines for inflammatory bowel disease, including ulcerative colitis and Crohn’s disease. Its research focuses on therapies designed to target immune pathways involved in these conditions. The company’s pipeline includes investigational antibodies targeting TL1A, IL-23 and integrin α4β7, as well as potential combinations of these approaches. Spyre has no approved products, and its candidates remain in development. Spyre was formed in 2023 through a business combination with Aeglea BioTherapeutics, which subsequently adopted the Spyre Therapeutics name. The company is based in the United States and is focused on developing treatments for patients with inflammatory bowel disease.AI Generated. May Contain Errors. Read More Spyre Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks37th Percentile Overall ScoreSYRE MarketRank™: 1.85121817684 of 5 starsSpyre Therapeutics scored higher than 37% of companies evaluated by MarketBeat, and ranked 1269th out of 1,704 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.2 / 5Analyst RatingModerate Buy Consensus RatingSpyre Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.94, and is based on 2 strong buy ratings, 13 buy ratings, 1 hold rating, and 1 sell rating.Upside/DownsideThe consensus price target for Spyre Therapeutics is close to its current price, suggesting limited near-term upside or downside.Amount of Analyst CoverageSpyre Therapeutics has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Spyre Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Spyre Therapeutics are expected to decrease in the coming year, from ($2.78) to ($3.78) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Spyre Therapeutics is -37.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Spyre Therapeutics is -37.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSpyre Therapeutics has a P/B Ratio of 10.65. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted14.51% of the float of Spyre Therapeutics has been sold short.Short Interest Ratio / Days to CoverSpyre Therapeutics has a short interest ratio ("days to cover") of 12.69, which indicates bearish sentiment.Change versus previous monthShort interest in Spyre Therapeutics has recently decreased by 7.10%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSpyre Therapeutics does not currently pay a dividend.Dividend GrowthSpyre Therapeutics does not have a long track record of dividend growth. News and Social Media2.0 / 5News Sentiment0.20 News SentimentSpyre Therapeutics has a news sentiment score of 0.20. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.38 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Spyre Therapeutics this week, compared to 4 articles on an average week.Search Interest2 people have searched for SYRE on MarketBeat in the last 30 days. Company Ownership2.0 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Spyre Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $12,349,518.00 in company stock.Percentage Held by Insiders15.69% of the stock of Spyre Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions80.39% of the stock of Spyre Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Spyre Therapeutics' insider trading history. Receive SYRE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Spyre Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SYRE Stock News HeadlinesSpyre’s SKYLIGHT Trial Advances as SPY072 Enters Phase 2 TestingNovember 18 at 11:51 AM | tipranks.comSpyre Therapeutics, Inc. (SYRE) Presents at UBS Global Biopharma Conference 2026 TranscriptNovember 16 at 12:38 PM | seekingalpha.comThe Democrats can’t stop thisPorter Stansberry believes President Trump has begun a full dollar reset through executive order 14241, bypassing Congress under a national emergency. His new briefing outlines three steps to prepare and names a core group of assets tied to the initiative that he says could surge. He points to the 1970s Nixon-era reset, which reportedly minted an average of 1,300 new millionaires a day for over half a century.November 19 at 1:00 AM | Porter & Company (Ad)Spyre Therapeutics to Participate in Upcoming Investor ConferencesNovember 10, 2026 | marketscreener.comMSpyre Therapeutics, Inc. (NASDAQ:SYRE) Stock Has Consensus Price Target of $110.40November 9, 2026 | americanbankingnews.comSpyre Therapeutics (SYRE) Stock Trades At A Premium To Book ValueNovember 8, 2026 | uk.finance.yahoo.comAnalysts Offer Insights on Healthcare Companies: Lemaitre Vascular (LMAT), Spyre Therapeutics (SYRE) and Alnylam Pharma (ALNY)November 6, 2026 | theglobeandmail.comSpyre Therapeutics Announces Grants of Inducement AwardsNovember 6, 2026 | globenewswire.comSee More Headlines SYRE Stock Analysis - Frequently Asked Questions How have SYRE shares performed this year? Spyre Therapeutics' stock was trading at $32.76 at the start of the year. Since then, SYRE stock has increased by 209.7% and is now trading at $101.46. How were Spyre Therapeutics' earnings last quarter? Spyre Therapeutics, Inc. (NASDAQ:SYRE) released its quarterly earnings results on Tuesday, November, 3rd. The company reported ($0.94) EPS for the quarter, missing the consensus estimate of ($0.82) by $0.12. When did Spyre Therapeutics IPO? Spyre Therapeutics (SYRE) raised $85 million in an initial public offering (IPO) on Wednesday, April 6th 2016. The company issued 5,000,000 shares at a price of $16.00-$18.00 per share. Who are Spyre Therapeutics' major shareholders? Top institutional shareholders of Spyre Therapeutics include State Street Corp (3.72%), Goldman Sachs Group Inc. (1.27%), Assenagon Asset Management S.A. (0.59%) and Marshall Wace LLP (0.57%). Insiders that own company stock include Cameron Turtle, Scott L Burrows, Michael Thomas Henderson, Sheldon Sloan, Jeffrey W Albers, Heidy King-Jones and Fairmount Funds Management Llc. View institutional ownership trends. How do I buy shares of Spyre Therapeutics? Shares of SYRE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Spyre Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Spyre Therapeutics investors own include NVIDIA (NVDA), Micron Technology (MU), Advanced Micro Devices (AMD), Taiwan Semiconductor Manufacturing (TSM), Credo Technology Group (CRDO), Definium Therapeutics (DFTX) and Kratos Defense & Security Solutions (KTOS). Company Calendar Last Earnings11/03/2026Today11/19/20269th Annual Evercore ISI HealthCONx Conference12/01/2026Citi Annual Global Healthcare Conference 202612/02/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (12m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 SYRE's financial health is in the Green zone, according to TradeSmith. SYRE has been in this zone for over 12 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:SYRE Previous SymbolNASDAQ:SYRE CIK1636282 Webwww.spyre.com Phone(617) 651-5940Fax512-872-5121Employees130Year Founded2013Price Target and Rating Average Price Target for Spyre Therapeutics$110.53 High Price Target$135.00 Low Price Target$80.00 Potential Upside/Downside+12.1%Consensus RatingModerate Buy Rating Score (0-4)2.94 Research Coverage17 Analysts Profitability EPS (Trailing Twelve Months)($2.74) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$155.20 million Net MarginsN/A Pretax MarginN/A Return on Equity-35.97% Return on Assets-27.67% Debt Debt-to-Equity RatioN/A Current Ratio27.40 Quick Ratio27.40 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$9.53 per share Price / Book10.35Miscellaneous Outstanding Shares94,969,000Free Float80,068,000Market Cap$9.37 billion OptionableOptionable Beta3.24 7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free Report This page (NASDAQ:SYRE) was last updated on 11/19/2026 by MarketBeat.com Staff. From Our PartnersYour $7 scanner is waitingThe Instant Scanner is $7 in Bill Poulos's Black Friday sale. Every night it delivers a list showing which sto...Profits Run | SponsoredThe Democrats can’t stop thisPorter Stansberry believes President Trump has begun a full dollar reset through executive order 14241, bypass...Porter & Company | SponsoredTop Trader Reveals Stunning Black Friday DealOthers paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Tradi...Base Camp Trading | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredThe next convergence is hereIn 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This pa...Digest Publishing | SponsoredELON + YOU + DECEMBER 8THElon Musk's next big project may be the most ambitious move of his career, and all signs point to December 8th...Paradigm Press | Sponsored6 Men Secretly Changed America’s Money. Now It’s Happening AgainIn 1910, six powerful men secretly met to lay the groundwork for the Federal Reserve, reshaping America's fina...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Spyre Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Spyre Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.